Outlook Therapeutics, Inc.
OTLK
Positions held
Your positionsOTLK isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $137.30M | Enterprise value | $144.49M | Trailing P/E | — | Forward P/E | -4.70 |
| PEG | — | Price / book | -10.07 | Beta | 0.67 | Dividend yield | 0.00% |
| Revenue growth | -99.4% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -1242.6% |
| Profit margin | 0.0% | ROE | — | ROA | -143.2% | Debt / equity | — |
| Current ratio | 0.81 | Free cash flow | -$37.36M | Analyst recommendation | none | Mean target | $5.03 |
| 52w high | $2.54 | 52w low | $0.16 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.1M | -$1.2M | -$0.1M | $1.5M | — |
| Op margin | -124255.3% | -11006.8% | 1116.4% | 18863.9% | -1046.2% | — |
| Net income | -$20.3M | -$4.5M | -$23.1M | -$13.3M | -$20.2M | — |
| Gross margin | -95.0% | -17.2% | 102.5% | 1098.5% | 70.8% | — |
| Gross profit | -$0.0M | -$0.0M | -$1.2M | -$1.0M | $1.1M | — |
| Operating income | -$10.8M | -$14.0M | -$13.5M | -$17.3M | -$15.7M | — |
- Revenue -93% vs prior quarter ($0.0M vs $0.1M).
- Gross margin -95% (was -17.2% prior quarter).
- Operating margin compressed to -124255.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $1.4M | $0.0M | $0.0M | $0.0M |
| Op margin | -4744.3% | — | — | — |
| Net income | -$62.4M | -$75.4M | -$59.0M | -$66.1M |
| Gross margin | 4.0% | — | — | — |
| Gross profit | $0.1M | $0.0M | — | — |
| Operating income | -$67.1M | -$71.7M | -$53.1M | -$63.1M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
2026-09-28 · Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 183%
2026-09-11 · Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
2026-08-27 · Outlook Therapeutics Appoints Kevin Lundquist as CFO
2026-08-27 · Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
2026-08-17 · BC-Most Active Stocks
2026-08-17 · OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
2026-08-17 · Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing
2026-08-15 · Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet
Price (daily)
Full chart · RSI · MACD · patterns